Business Context and Reporting Period
This summary covers the Form 10-Q filed by Schering-Plough Corporation for the quarterly period ended September 30, 2002. The company is a global pharmaceutical and consumer health products manufacturer. The filing includes unaudited consolidated financial statements and management's discussion and analysis of financial condition and results of operations.
Key Financial Metrics
| Metric | Q3 2002 | Q3 2001 | 9 Months 2002 | 9 Months 2001 |
|---|---|---|---|---|
| Net Sales ($ millions) | $2,421 | $2,377 | $7,810 | $7,301 |
| Net Income ($ millions) | $429 | $601 | $1,662 | $1,800 |
| Diluted EPS ($) | $0.29 | $0.41 | $1.13 | $1.22 |
| Operating Cash Flow ($ millions) | N/A | N/A | $1,484 | $1,753 |
| Cash and Equivalents ($ millions) | $3,310 | N/A | $3,310 | N/A |
| Total Debt ($ millions) | $1,154 (Current) | N/A | $1,154 (Current) | N/A |
| Long-Term Debt ($ millions) | $1,074 | N/A | $1,074 | N/A |
Margins: Cost of sales as a percentage of sales increased to 26.6% in Q3 2002 from 20.4% in Q3 2001. Income before taxes represented 23.0% of sales in Q3 2002, down from 32.8% in the prior year.
Material Changes vs. Prior Period
- Revenue: Consolidated net sales increased 2% in Q3 2002 and 7% for the nine-month period compared to 2001. However, excluding foreign currency effects, sales decreased 1% in the quarter. International sales grew 21% in Q3, while U.S. sales declined 10%.
- Profitability: Net income decreased 29% in Q3 2002 and 8% for the nine-month period. Diluted earnings per share fell 29% in the quarter to $0.29.
- Product Performance:
- Allergy & Respiratory: Sales dropped 28% in Q3, driven by a 51% decline in CLARITIN family sales due to trade inventory reductions and conversion to the new product CLARINEX.
- Anti-infective & Anticancer: Sales surged 93% in Q3, led by the INTRON franchise (hepatitis C treatment) and growth in REMICADE and TEMODAR.
- Cardiovasculars: Sales fell 38% in Q3, primarily due to generic competition for K-DUR.
- Costs: Cost of sales increased due to a shift toward royalty-bearing products and manufacturing issues. R&D spending increased 14% in the quarter.
Guidance, Outlook, Risks, and Contingencies
- Guidance: Management projects 2003 earnings to be in the range of approximately $1.00 to $1.15 per share. This outlook accounts for the expected loss of CLARITIN prescription sales, potential generic ribavirin competition, and increased manufacturing costs.
- CLARITIN Transition: The company anticipates a significant negative impact on 2002 pretax profits (estimated at $250 million) due to the reduction of CLARITIN trade inventories in preparation for its switch to Over-The-Counter (OTC) status. Generic competition for loratadine is expected to enter the market as early as December 20, 2002.
- Consent Decree: Schering-Plough reached an agreement with the FDA regarding Good Manufacturing Practices (GMP) violations. The company agreed to pay $500 million to the U.S. government (first installment paid in May 2002). Failure to meet revalidation timelines could result in additional daily penalties and royalties on sales.
- Legal and Regulatory Risks:
- Patent Litigation: A federal court ruled certain desloratadine compound claims invalid; the company is appealing. Generic entry for CLARITIN and REBETOL remains a significant risk.
- Government Investigations: The company is cooperating with multiple investigations by the DOJ, FDA, and state attorneys general regarding marketing practices, Average Wholesale Price (AWP) reporting, and Medicaid rebates. These could result in fines, penalties, or exclusion from government programs.
- Biogen Settlement: The company settled two arbitrations with Biogen, agreeing to a one-time payment of $45–$50 million in Q4 2002 and future royalties on alpha interferon products.
- Credit Ratings: Standard & Poor's lowered the long-term credit rating to "AA-" with a negative outlook. Moody's placed the "Aa2" rating under review for possible downgrade.
Investor Verification Checklist
- CLARITIN OTC Approval Date: Verify the FDA's final decision on the OTC switch (targeted for late November 2002) and the actual timeline for generic loratadine market entry.
- Consent Decree Compliance: Monitor the company's progress on revalidation plans to avoid daily penalties and potential product seizures.
- Legal Exposure: Track the status of the desloratadine patent appeal and the outcomes of ongoing DOJ and state investigations into AWP and marketing practices.
- 2003 Earnings Realization: Assess whether the projected $1.00–$1.15 EPS range holds given the volatility in the allergy/respiratory segment and potential new generic entrants.
- Cash Flow Impact: Confirm the impact of the second $250 million consent decree payment due in Q2 2003 on liquidity.